http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 28 Aug 2026 08:30:39 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Novavax%27s+Nuvaxovid+wins+approval+in+U.S.%2C+EU%2C+Japan+for+2026-2027/26993354.html <p>Novavax, Inc. (Nasdaq: NVAX) announced that its partners have received regulatory approvals for an XFG variant-targeted formulation of Nuvaxovid for the 2026-2027 COVID-19 vaccination season in the U.S., European Union, and Japan, according to a company press release.</p><p>Sanofi, Novavax's largest partner, leads commercial activities for Nuvaxovid across most major markets. For the upcoming season, Sanofi plans to expand its U.S. marketing campaign and launch the vaccine in Germany, Canada, and other international markets. Novavax is eligible to receive royalties on net sales under a 2024 collaboration and license agreement with Sanofi.</p><p>Takeda commercializes Nuvaxovid in Japan, where the vaccine ranked as http://www.streetinsider.com/Corporate+News/Novavax%27s+Nuvaxovid+wins+approval+in+U.S.%2C+EU%2C+Japan+for+2026-2027/26993354.html Fri, 28 Aug 2026 08:30:39 -0400 NVAX http://www.streetinsider.com/FDA/Novavax%27s+Nuvaxovid+wins+approval+in+U.S.%2C+EU%2C+Japan+for+2026-2027/26993354.html <p>Novavax, Inc. (Nasdaq: NVAX) announced that its partners have received regulatory approvals for an XFG variant-targeted formulation of Nuvaxovid for the 2026-2027 COVID-19 vaccination season in the U.S., European Union, and Japan, according to a company press release.</p><p>Sanofi, Novavax's largest partner, leads commercial activities for Nuvaxovid across most major markets. For the upcoming season, Sanofi plans to expand its U.S. marketing campaign and launch the vaccine in Germany, Canada, and other international markets. Novavax is eligible to receive royalties on net sales under a 2024 collaboration and license agreement with Sanofi.</p><p>Takeda commercializes Nuvaxovid in Japan, where the vaccine ranked as http://www.streetinsider.com/FDA/Novavax%27s+Nuvaxovid+wins+approval+in+U.S.%2C+EU%2C+Japan+for+2026-2027/26993354.html Fri, 28 Aug 2026 08:30:39 -0400 NVAX http://www.streetinsider.com/Press+Releases/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html <div class="xn-content"> <ul type="disc"><li><i>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations</i>¹</li><li><i><span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax's</span> partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gaiurg" idsrc="xmltag.org" >GAITHERSBURG, Md.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax, Inc.'s</span> (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <span value="ACORN:5020211746" idsrc="xmltag.org">European Union</span> (<span value="ACORN:5020211746" idsrc="xmltag.org">EU</span>) and <location value="LC/jp" http://www.streetinsider.com/Press+Releases/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html Fri, 28 Aug 2026 08:30:00 -0400 A.50202117 NVAX O.00174209 O.37382289 http://www.streetinsider.com/Press+Releases/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html <div class="xn-content"> <ul type="disc"><li><i>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations</i>¹</li><li><i><span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax's</span> partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gaiurg" idsrc="xmltag.org" >GAITHERSBURG, Md.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax, Inc.'s</span> (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <span value="ACORN:5020211746" idsrc="xmltag.org">European Union</span> (<span value="ACORN:5020211746" idsrc="xmltag.org">EU</span>) and <location value="LC/jp" http://www.streetinsider.com/Press+Releases/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html Fri, 28 Aug 2026 08:30:00 -0400 A.50202117 NVAX O.00174209 O.37382289 http://www.streetinsider.com/Press+Releases/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html <div class="xn-content"> <ul type="disc"><li><i>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations</i>¹</li><li><i><span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax's</span> partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gaiurg" idsrc="xmltag.org" >GAITHERSBURG, Md.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax, Inc.'s</span> (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <span value="ACORN:5020211746" idsrc="xmltag.org">European Union</span> (<span value="ACORN:5020211746" idsrc="xmltag.org">EU</span>) and <location value="LC/jp" http://www.streetinsider.com/Press+Releases/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html Fri, 28 Aug 2026 08:30:00 -0400 A.50202117 NVAX O.00174209 O.37382289 http://www.streetinsider.com/Press+Releases/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html <div class="xn-content"> <ul type="disc"><li><i>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations</i>¹</li><li><i><span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax's</span> partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gaiurg" idsrc="xmltag.org" >GAITHERSBURG, Md.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax, Inc.'s</span> (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <span value="ACORN:5020211746" idsrc="xmltag.org">European Union</span> (<span value="ACORN:5020211746" idsrc="xmltag.org">EU</span>) and <location value="LC/jp" http://www.streetinsider.com/Press+Releases/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html Fri, 28 Aug 2026 08:30:00 -0400 A.50202117 NVAX O.00174209 O.37382289 http://www.streetinsider.com/PRNewswire/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html <div class="xn-content"> <ul type="disc"><li><i>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations</i>¹</li><li><i><span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax's</span> partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gaiurg" idsrc="xmltag.org" >GAITHERSBURG, Md.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax, Inc.'s</span> (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <span value="ACORN:5020211746" idsrc="xmltag.org">European Union</span> (<span value="ACORN:5020211746" idsrc="xmltag.org">EU</span>) and <location value="LC/jp" http://www.streetinsider.com/PRNewswire/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html Fri, 28 Aug 2026 08:30:00 -0400 A.50202117 NVAX O.00174209 O.37382289 http://www.streetinsider.com/PRNewswire/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html <div class="xn-content"> <ul type="disc"><li><i>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations</i>¹</li><li><i><span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax's</span> partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gaiurg" idsrc="xmltag.org" >GAITHERSBURG, Md.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax, Inc.'s</span> (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <span value="ACORN:5020211746" idsrc="xmltag.org">European Union</span> (<span value="ACORN:5020211746" idsrc="xmltag.org">EU</span>) and <location value="LC/jp" http://www.streetinsider.com/PRNewswire/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html Fri, 28 Aug 2026 08:30:00 -0400 A.50202117 NVAX O.00174209 O.37382289 http://www.streetinsider.com/PRNewswire/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html <div class="xn-content"> <ul type="disc"><li><i>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations</i>¹</li><li><i><span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax's</span> partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gaiurg" idsrc="xmltag.org" >GAITHERSBURG, Md.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax, Inc.'s</span> (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <span value="ACORN:5020211746" idsrc="xmltag.org">European Union</span> (<span value="ACORN:5020211746" idsrc="xmltag.org">EU</span>) and <location value="LC/jp" http://www.streetinsider.com/PRNewswire/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html Fri, 28 Aug 2026 08:30:00 -0400 A.50202117 NVAX O.00174209 O.37382289 http://www.streetinsider.com/PRNewswire/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html <div class="xn-content"> <ul type="disc"><li><i>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations</i>¹</li><li><i><span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax's</span> partners are ready to bring its protein-based, non-mRNA vaccine with a favorable tolerability profile to global markets, providing an important option for healthcare providers and patients</i></li></ul><p><span class="legendSpanClass"><location value="LU/us.md.gaiurg" idsrc="xmltag.org" >GAITHERSBURG, Md.</location></span>, <span class="legendSpanClass"><chron>Aug. 28, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax, Inc.'s</span> (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the <location value="LC/us" idsrc="xmltag.org" >U.S</location>., <span value="ACORN:5020211746" idsrc="xmltag.org">European Union</span> (<span value="ACORN:5020211746" idsrc="xmltag.org">EU</span>) and <location value="LC/jp" http://www.streetinsider.com/PRNewswire/Novavax%27s+Partnership+Strategy+Continues+to+Deliver+with+XFG-adapted+Nuvaxovid%E2%84%A2+Approvals+in+the+U.S.%2C+EU+and+Japan+for+2026-2027+Vaccination+Season/26993346.html Fri, 28 Aug 2026 08:30:00 -0400 A.50202117 NVAX O.00174209 O.37382289 http://www.streetinsider.com/Options/Novavax+%28NVAX%29+11K+contracts+of+August+28+weekly+9+calls+trade%2C+share+price+up+8.8%25/26949735.html <p>Novavax (NASDAQ: NVAX) 30-day option implied volatility is at 69; compared to its 52-week of 50 to 105 with a focus on 11K contracts of August 28 weekly 9 calls as share price up 8.8%.</p> http://www.streetinsider.com/Options/Novavax+%28NVAX%29+11K+contracts+of+August+28+weekly+9+calls+trade%2C+share+price+up+8.8%25/26949735.html Wed, 19 Aug 2026 15:20:19 -0400 NVAX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NOVAVAX+INC++++++++++++++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888967.html si-local-file:///var/storage/secattach/20260807/26888967.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NOVAVAX+INC++++++++++++++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888967.html Fri, 07 Aug 2026 10:26:00 -0400 NVAX O.00174209 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NOVAVAX+INC++++++++++++++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888967.html si-local-file:///var/storage/secattach/20260807/26888967.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++NOVAVAX+INC++++++++++++++++++++++++++++Filed+by%3A+STATE+STREET+CORP/26888967.html Fri, 07 Aug 2026 10:26:00 -0400 NVAX O.00174209 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NOVAVAX+INC++++++++++++++++++++++++++/26883249.html si-local-file:///var/storage/secattach/20260806/26883249.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NOVAVAX+INC++++++++++++++++++++++++++/26883249.html Thu, 06 Aug 2026 16:01:00 -0400 NVAX O.00174209 http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NOVAVAX+INC++++++++++++++++++++++++++/26883249.html si-local-file:///var/storage/secattach/20260806/26883249.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++NOVAVAX+INC++++++++++++++++++++++++++/26883249.html Thu, 06 Aug 2026 16:01:00 -0400 NVAX O.00174209 http://www.streetinsider.com/Earnings/Novavax+%28NVAX%29+Tops+Q2+EPS+by+8c/26879435.html <p>Novavax (NASDAQ: NVAX) reported Q2 EPS of ($0.32), $0.08 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $57 million versus the consensus estimate of $52.06 million.</p><p>For earnings history and earnings-related data on Novavax (NVAX) <a href="http://www.streetinsider.com/ec_earnings.php?q=NVAX">click here</a>.</p> http://www.streetinsider.com/Earnings/Novavax+%28NVAX%29+Tops+Q2+EPS+by+8c/26879435.html Thu, 06 Aug 2026 08:09:47 -0400 NVAX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NOVAVAX+INC+++++++++++++++For%3A+Aug+06/26879332.html si-local-file:///var/storage/secattach/20260806/26879332.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NOVAVAX+INC+++++++++++++++For%3A+Aug+06/26879332.html Thu, 06 Aug 2026 08:03:00 -0400 NVAX O.00174209 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NOVAVAX+INC+++++++++++++++For%3A+Aug+06/26879332.html si-local-file:///var/storage/secattach/20260806/26879332.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++NOVAVAX+INC+++++++++++++++For%3A+Aug+06/26879332.html Thu, 06 Aug 2026 08:03:00 -0400 NVAX O.00174209 http://www.streetinsider.com/Press+Releases/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html <div class="xn-content"> <ul type="disc"><li><i>Reported total revenue of <money>$57 million</money> for the second quarter of 2026 and raised full-year 2026 Revenue Framework </i></li><li><i>Improved</i> <i>GAAP Combined R&amp;D and SG&amp;A expense guidance by <money>$10 million</money> at mid-point</i> </li><li><i>Sanofi confirmed with <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span> that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment</i></li><li><i>Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a <money>$75 million</money> milestone payment to <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span></i></li><li><i>Multiple partner-led experiments with Matrix-M are currently underway in a wide array http://www.streetinsider.com/Press+Releases/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html Thu, 06 Aug 2026 08:00:00 -0400 A.06822034 NVAX O.00174209 O.20026344 http://www.streetinsider.com/Press+Releases/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html <div class="xn-content"> <ul type="disc"><li><i>Reported total revenue of <money>$57 million</money> for the second quarter of 2026 and raised full-year 2026 Revenue Framework </i></li><li><i>Improved</i> <i>GAAP Combined R&amp;D and SG&amp;A expense guidance by <money>$10 million</money> at mid-point</i> </li><li><i>Sanofi confirmed with <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span> that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment</i></li><li><i>Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a <money>$75 million</money> milestone payment to <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span></i></li><li><i>Multiple partner-led experiments with Matrix-M are currently underway in a wide array http://www.streetinsider.com/Press+Releases/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html Thu, 06 Aug 2026 08:00:00 -0400 A.06822034 NVAX O.00174209 O.20026344 http://www.streetinsider.com/Press+Releases/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html <div class="xn-content"> <ul type="disc"><li><i>Reported total revenue of <money>$57 million</money> for the second quarter of 2026 and raised full-year 2026 Revenue Framework </i></li><li><i>Improved</i> <i>GAAP Combined R&amp;D and SG&amp;A expense guidance by <money>$10 million</money> at mid-point</i> </li><li><i>Sanofi confirmed with <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span> that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment</i></li><li><i>Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a <money>$75 million</money> milestone payment to <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span></i></li><li><i>Multiple partner-led experiments with Matrix-M are currently underway in a wide array http://www.streetinsider.com/Press+Releases/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html Thu, 06 Aug 2026 08:00:00 -0400 A.06822034 NVAX O.00174209 O.20026344 http://www.streetinsider.com/Press+Releases/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html <div class="xn-content"> <ul type="disc"><li><i>Reported total revenue of <money>$57 million</money> for the second quarter of 2026 and raised full-year 2026 Revenue Framework </i></li><li><i>Improved</i> <i>GAAP Combined R&amp;D and SG&amp;A expense guidance by <money>$10 million</money> at mid-point</i> </li><li><i>Sanofi confirmed with <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span> that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment</i></li><li><i>Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a <money>$75 million</money> milestone payment to <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span></i></li><li><i>Multiple partner-led experiments with Matrix-M are currently underway in a wide array http://www.streetinsider.com/Press+Releases/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html Thu, 06 Aug 2026 08:00:00 -0400 A.06822034 NVAX O.00174209 O.20026344 http://www.streetinsider.com/PRNewswire/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html <div class="xn-content"> <ul type="disc"><li><i>Reported total revenue of <money>$57 million</money> for the second quarter of 2026 and raised full-year 2026 Revenue Framework </i></li><li><i>Improved</i> <i>GAAP Combined R&amp;D and SG&amp;A expense guidance by <money>$10 million</money> at mid-point</i> </li><li><i>Sanofi confirmed with <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span> that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment</i></li><li><i>Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a <money>$75 million</money> milestone payment to <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span></i></li><li><i>Multiple partner-led experiments with Matrix-M are currently underway in a wide array http://www.streetinsider.com/PRNewswire/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html Thu, 06 Aug 2026 08:00:00 -0400 A.06822034 NVAX O.00174209 O.20026344 http://www.streetinsider.com/PRNewswire/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html <div class="xn-content"> <ul type="disc"><li><i>Reported total revenue of <money>$57 million</money> for the second quarter of 2026 and raised full-year 2026 Revenue Framework </i></li><li><i>Improved</i> <i>GAAP Combined R&amp;D and SG&amp;A expense guidance by <money>$10 million</money> at mid-point</i> </li><li><i>Sanofi confirmed with <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span> that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment</i></li><li><i>Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a <money>$75 million</money> milestone payment to <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span></i></li><li><i>Multiple partner-led experiments with Matrix-M are currently underway in a wide array http://www.streetinsider.com/PRNewswire/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html Thu, 06 Aug 2026 08:00:00 -0400 A.06822034 NVAX O.00174209 O.20026344 http://www.streetinsider.com/PRNewswire/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html <div class="xn-content"> <ul type="disc"><li><i>Reported total revenue of <money>$57 million</money> for the second quarter of 2026 and raised full-year 2026 Revenue Framework </i></li><li><i>Improved</i> <i>GAAP Combined R&amp;D and SG&amp;A expense guidance by <money>$10 million</money> at mid-point</i> </li><li><i>Sanofi confirmed with <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span> that they are in advanced discussions with regulators regarding their Phase 3 COVID-19-Influenza Combination trial timing and intend to be among the first movers in the combination vaccine segment</i></li><li><i>Completion of manufacturing technology transfer to Sanofi expected in mid-2027 and would trigger a <money>$75 million</money> milestone payment to <span value="NASDAQ-NMS:NVAX" idsrc="xmltag.org" >Novavax</span></i></li><li><i>Multiple partner-led experiments with Matrix-M are currently underway in a wide array http://www.streetinsider.com/PRNewswire/Novavax+Reports+Second+Quarter+2026+Financial+Results+and+Operational+Highlights/26879154.html Thu, 06 Aug 2026 08:00:00 -0400 A.06822034 NVAX O.00174209 O.20026344